Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3839743 A
Publication typeGrant
Publication dateOct 8, 1974
Filing dateOct 15, 1973
Priority dateApr 21, 1972
Publication numberUS 3839743 A, US 3839743A, US-A-3839743, US3839743 A, US3839743A
InventorsA Schwarcz
Original AssigneeA Schwarcz
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Method for maintaining the normal integrity of blood
US 3839743 A
Abstract
Thromboresistant biomedical articles are provided which are useful in the fields of subdermal surgical implants, laboratory apparatus and blood containers. These articles have at least a thin surface coating of an organic polymeric material having fluoroalkyl side chains and simple anionic side groups.
Images(7)
Previous page
Next page
Description  (OCR text may contain errors)

United States'Patent [191 3/36; 128/214 R, 214 D, 334 R, 348, 349 R, 350 R, 335.5, 303; 117/124 R, 138.8 A,

Schwarcz 1 Oct. 8, 1974 [54] METHOD FOR MAINTAINING THE [56] References Cited NORMAL INTEGRITY OF BLOOD UNITED STATES EN [76] Inventor: 'Andor Schwarcz, 2117 McClellan 3,633,578 l/l972 Roth,.... 3/1 X St., Schenectady, N Y, 12309 3,663,288 5/1972 Miller 117/138.8 A X 3,722,599 3/1973 Robertson 128/334'R [22] Filed: Oct. 15, 1973 [21,] Appl' 406,547 4 Primary Examiner-Richard A. Gaudet Related U.S.'Application Data 7 Assistant ExaminerRona1 d L. Frinks [63] Continuation-impart of Ser. No. 246,327, April 21,

I 1972, abandoned. ABSTRACT I 52 US. Cl 3/1, 3/1310. 1, 3/D1G. 2, Thromboresistam biomedical articles. are provided 3 3 3 3 23 214 R, 123 2 4 1), which are useful in the fields of sub'dermal surgical im- 128/348, 128/350 R, 117/124 E, plants, laboratory apparatus and b1ood containers. Y Y 1 17/1383 A These articles haveat least a thin surface coating of an 51 Int. Cl ..A61'f 1/ 24, A6lf 1/22, A61m 5/00 Organic polymeric material having fluoroalkyl side ["Sfi "FiFl'ibf SEiicHlI.'I.I.'..L..'. 3/"1, DIG 'I' DI G. 3, Chalns and Simple 9 slde F P 19 Claims, N0 Drawings METHOD FOR MAINTAI NING THE NORMAL INTEGRITY OF BLOOD This is a continuation-in-part of application Ser. No. 246,327, filed Apr. 21, 1972 and now abandoned.

BACKGROUND OF THE INVENTION 1. Field of the invention This invention relates to biomedical articles that resist the clotting of human blood and generally that of warm blooded animals. It describes the structure of these-articles and the various modes of their manufacture. One of such articles is a subdermal implant. Examples are subdermal prosthesis such as artificial blood vessels to correct atherosclerotic shrunken passage- 1 ways or to eliminate aneurisms in cardiac assist devices .and in artifical hearts and heart valves to replace or augment the function of the natural heart. Other subdermal prosthetic devices of this invention include reinforced and non reinforced sheetings, rubbers to reconstruct fractures, coronary arteries, denture soft liners, denture base materials, sponge subdermal implant materials, mammary prosthesis, testicular prosthesis, atoplasty prosthesis, rhinoplasty implants, scleral buckler drains, catheters for intravenous administration of flu ids for withdrawal of serial blood samples, for percuta' neous flow-guided cardia catheterization, continuous monitoring of blood glucose, intestinal decompression tubes, various catheters and thoriac drains. Other implanted articles of this invention include circulatory assist devices, tubes for blood transfusion, the implants of electrical devices and mechanical devices such as prosthetic valves and sutures. Other biomedical articles of this invention include thromboresistant surgical instru- 'rnents, laboratory apparatus used for blood handling and blood handling and blood containers for storage.

2. Description of the Prior Art One of the most striking property of blood is its tendency to undergo clotting, or thrombosis. This has been the major problem encountered in the use of subdennal prosthesis.

The detailed mechanisme of thrombosis is still not established. Its normal course involves a series of com-' plex reactions that, once initiated result in the formation of thrombosis. Two processes may occur:

1. The absorption of proteins leading to coagulation;

,thrombogenic and therefore require the use by the patient of anticoagulant drugs such as heparin and coumarin derivatives.

,Various organic polymers'havebeen coated recently with heparin. Although this material displays some degree of thromboresistance, the coating eventually washes away with the flow of blood and it is difficult to fabricate. i

There have been attempts to obtain thromboresistant biomedical articles from fluorinated polymers and sulfonated polymers. However, none of them are performing in a satisfactory manner. This is due, in the opinion of the author of the present invention, to the disposition, the length and the relative lengths of the various groups in the polymer.

SUMMARY OF THE INVENTION.

My invention provides,thromboresistant biomedical articles useful in the fields of subdermal implants, surgical instruments, laboratory apparatus and blood containers. These articles are composed, at least on their surface, of an organic polymeric material having side chains of the formula C,,F ,C,,,l-l ,wherein n and m are integers, n ranging from 1 to 28 and the sum of n and m from 1 to 28, and an anionic group.

DESCRIPTION or THE PREFERRED EMBODIMENT The biomedical articles of this invention are characterized by their thromboresistant surface. The surface of the said articles are characterized by an organic polymeric material having fluoroalkyl side chains of the nF2nJ-l m 2m and m are integers, the range of )1 extending from 1 to 28 and the sum of n and in from 2 to 28. Thenurnberof fluoroalkyl side chains relative to the number of main-chain-atoms in one recurring unit ranges from 1:2 to lzlQ preferably from 1:2 to 1:5.The atoms that arch the main or linear direction of the polymer such as the carbon atoms in polyethylene and poly vinyl alcohol), are the only ones considered main-chain-atoms. Linear fluoroalkyl side chains with values of the integer rt ranging from 8 to 28 are particularly effective ones to give the articles of this invention a high degree of thromboresistance.

The presence of another, generally shorter side chain, which is an anion or one comprising an anion, generally enhances the 'thromboresistivity of the polymer. However, its presence is required only in the cases wherein the said fluoroalkyl side chain is branched (non linear) and in cases wherein the value of the integer n ranges from 1 to 7. i

A feature of the 'said organic polymeric materials of I this invention is thattheir thromboresistant character.

invcntion'have simultaneously low surface tension and negative zeta potential, properties thought necessary for thromboresistance according to certain theories.

The invention is described hereinafter in. greater detail by reference to the examples which show preferred embodiments of the invention. It should be understood however that the examples hereinafter given are for the purposes of illustration only and that the invention in its broader aspects is not limited thereto.

Examples of the said tluorinated side chains are 3( 2)1 CF3(CF2)11(CH2)16 1 a 2)22 2 4 9( 2)10."- H2)2 a 1' The anionic groups can be either in their acidic form, their salt or their partially neutralized form. Example of 3 simple anionic groups are carboxylate, sulfonate, sulfate, phosphate and phosphites. Examples of the salt forming positive ions are sodium, potassium, lithium, ammonium, magnesium, tertiary amines such as N- methylmorpholine.

The ratio of the number of the said fluoroalkyl groups to the number of said anionic groups ranges from 0.511 to 50:1, preferably from 1:1 to 20:1. ln general, this ratio decreases as the ionic strength decreases. The number, strength and degree of neutralization of said anionic groups should be limited in order to avoid solvation or excessive swelling of the fluorinated polymer by the blood.

The said fluoroalkyl side chain may be directly attached to the main chain of the organic polymer. It can also be attached by an intermediate divalent radical,

such as --O, CO, SO, SO SO NH.-, CH O, COO-, NHCO, NH- COO, NHCONH-, POCH POC H SO NCH SO NC l-l Similarly, the anionic group may be directly attached to the main chain of the organic polymer or through an intermediate divalent radical. Such radicals are exemplified by CH C H OC H (CH )s 2 2H43( 2)i5 Biomedical articles of this invention may be entirely composed of the said organic polymeric materialswith the fluoroalkyl side chains. However, the particular mechanical and electrical properties required of the various biomedical articles, or the higher cost involved may require them to comprise a surface portion and a substrate portion. The surface portion is composed of the said thromboresistant organic polymer. The substrate portion may be any solid material that satisfies the properties required of the biomedical article. Thus, substrate materials comprise plastics, rubbers, metals, glass, ceramics. The useof a coating technic is particularly advantageous for making surgical instruments, laboratory apparatus, blood containers and heart valves.

Examples of plastic substrates are isotactic polyolefins, such as polypropylene, polystyrene, polyethylene, poly(4-methylpentane); polyesters such as poly(l,4- cyclohexylene terephthalate), poly(ethylene terephthalate); polyacrylates such as polymethylmethacrylate, polyco (ethylacrylate-acrylic acid); polyurethanes such as the ones prepared from a hydroxy. terminated polyether or polyester and methylenebis (phenylisocyanate); polycarbonates such as poly(2,2- propanebis(4-phenyl carbonate); fluorinated polyole fins such as poly(tetrafluoroethylene); chlorinated polyolefins such as polyvinylchloride; proteins such as wool, casein; cellulose, cellulose derivatives such as cellulose acetate, cellulose acetate butyrate and other polysaccharides. Examples of rubber substrates are silicone rubbers such as poly(dimethylsiloxane poly(rnethylphenyl siloxane); hydrocarbon rubbers such as butyl rubber, ethylene-propylene rubber; nitrile rubbers such as polyco(butadieneacrylonitrile); fluorinated rubbers such as fluorinated ethylene-propylene rubber, fluorinated polyurethanes; urethane rubbers such as the ones prepared from hydroxy terminated polyethers or polyesters and methylenebis(- phenylisocyanate); polyether rubbers such as poly (propylene oxide) and chlorosulfonated rubbers such as chlorosulfonated ethylene-propylene rubber.

Metallic substrates include stainless steel, aluminum, alloys of chromium, nickel, cobalt and magnesium.

Examples of the said organic polymeric materials having linear fluoroalkyl side chains wherein the said integer n ranges between 8 and 28, the sum of n and m between 8 and 28 and the said polymer has no anionic groups attached to the main chain are:

poly( l, l ,2,2- tetrahydropentadecafluorononyl acrylate) poly( l ,ldihydropentacosafluorotridecyl acrylate) poly( l,1dihydropentatetracontafluorotricosyl methacrylate) poly( 1,1 ,2,2-tetrahydrononacosafluorohexadecyl vinyl ehter) poly (vinylperfluorooctadecane) poly (perfluorol octadecene) poly(vinyl perfluorostearate) poly(N-l l dihydropentatriacontafluorooctadecyl hexamethylene urea) I poly(methyll ,l ,2,2-tetrahydrotritriacontafluorooctadecyl siloxane) poly [di( l,l,2,Z-tetrahydrotricosafluorotridecyl) siloxane] I poly( N-l 1 dihydropentatriacontafluorooctadecyl hexamethylene adipamide).

Examples of said organic polymeric materials having linear or branched fluoroalkyl side chains wherein the said integer n ranges between 1 and 28, the sum of n and m between 2 and 28 and the said anionic group is bonded to the main chain of the polymer, are (the propertion of monomers in the copolymers are expressed in mole polyco( l l dihydropentadecafluorooctyl methacrylate 10% sodium acrylate) polyco (l,l,2,2,stetrahydrotrifluoropropyl acrylate 5% maleic acid) polyco( 1,1 ,2,2-tetrahydropentade cafluorononyl acrylate 30% methacrylic acid 15% sodium methacrylate) poly(carboxyethyl-l l ,2,2-tetrahydrotrifluoropropyl siloxane) polyco(methyl-3,3,3-trifluoropropyl siloxane 20% carboxyethyl-methyl siloxane) polymers of fluoroalkyl esters, amides and imides of maleic and fumaric acids The copolymers with ethylene, styrene, methylvinyl ether and vinyl acetate of fluoroalkyl esters, amides and imides of maleic and fumaric acids The copolymers with maleic, fumaric and acrylic acids and their anhydrides of fluoroalkyl esters, amides and imides of maleic and fumaric acids the l,1dihydronanafluoropentyl monoester of polyco (50% ethylene 23% maleic acid 23% potassium maleate) the l,l-dihydropentadecafluorooctyl monoamide of polyco methylvinyl ether 10% fumaric acid 10% sodium fumarate) polyco( vinyl l l dihydropentatriacontafluorooctadecyl carbamate 15% vinyl disodium phosphite) polyco (vinyl perfluoropropianate 10% acrylic acid) These compounds are all linear organic polymers having intrinsic viscosity values higher than 0.04, preferably higher than 0.07. They can, be prepared by conventional polymerization techniques such as the free radical and ionic addition polymerization techniques or heat, oxygen, moisture, radiation, peroxides etc.

condensation polymerization techniques of the monomers. Another method consists of introducing an anigroup. Such compounds are, for example, perfluorooctadecanoyl chloride and l ,l-dihydrotricosafluorodode- 1 cyl alcohol. These techniques are well documented in the art of polymer synthesis.

After preparation, the polymer is then shaped into the desired biomedical articles, e.g. heart valves, blood vessel, tubings etc. The shaping can be done by any conventional means, uch as extruding,'molding, casting. After proper sterilization, the biomedical article is ready for use.

An effective way to prepare a thromboresistant biomedical article of this invention is to react the polymeric material of this invention containing the said anionic group with a stochiometrically defective amount of a cationic type polymer, such as poly-2- vinylpyridine, poly(vinylbenzyldimethylamine), polyco(styrene-4-vinylpyrridine).

Another way to prepare a thromboresistant biomedical article of this invention is to coat the potentially blood contacting surfaces of the shaped article made of a plastic, a rubber, a metal or glass with the said organic polymeric material having the fluoroalkyl side chains exemplified above. Any of the conventional coating procedures can be used, such as coating from a'solution, emulsion, suspension followed by solvent evaporation, or a hot melt coating technique. The bond between he substrate and the coating can be improved, if necessary, by conventional surface treatment techniques, such as corona discharge, flame treatment, irradiation, or priming with a polar polymeric substance. These coating and priming procedures are well documented in the art of coating technology.

A biomedical article of this invention can be prepared by the use of still another technique. This technique consists of coating the shaped article, made of a plastic, a rubber, a metal or glass, with the monomers from which the said organic polymeric materials, having the fiuoroalkyl side chains, and examplified above, are prepared, and let the polymerization proceed on the surface. Similar coating and priming procedures can be used as the onesdescribed above. The polymerization on the surface of the article can be carried out by conventional techniques used in the art of polymer synthesis and coatings, such as the use of catalysts,

Still another way to achieving the objectives of this invention is to graft an anionic group and the said pertluoroalkyl group C F ,C l-l onto the surface of a shaped biomedical article made of a plastic or a rubber. Examples of such surface grafting reactions are as follows:

the grafting of perfluorooctadecanoyl chloride onto a shaped biomedical article made of poly(tet-' ramethylene urea), poly(tetramethylene hexamethylene dicarbamate), cellulose fibers, wool, silk, nylon;

the grafting of sulfuric acid and perfluorohexadecanoic acid onto the shaped article made of poly(vinylalcohol), cellulose, casein;

the grafting of 1,1 ,2,2-tetrahydroheptafluoropentanol, onto a preshaped article made of polyco(acrylic acid sodium acrylate);

the grafting of l,l-dihydropentacosafluorotridecyl' iodide onto a shaped article made of polyco(ethylene-monosodium maleate), and onto sodium cellulose sulfate;

- the radiation grafting of l,l,2,Z-tetrahydrotritriacontafluorooctadecyl vinylether to a shaped article made of poly(ethylene ter'ephtalate);

the grafting of l,l-dihydrohencosafluoroundecyl amine onto a shaped biomedical article made of polyethylene which has been previously sulfonated with concentrated sulfuric acid and the sulfonate groups partially neutralized with a buffer solution having a pH of 7.5.

There are still other meansto prepare the polymers of this invention. For example polymers having unbr'anched higher alkyl side chains can be fiuorinated with fluorine gas. Examples of such polymers are polyvinylstearate, polyco(vinylacetate-docosylmaleate sodium salt).

EXAMPLE 1 Ninety grams (0.1 moles) of 1,1- dihydrotritriacontafluoroheptadecyl acrylate and 1.14 grams (0.0l moles) of l-hexenoic acid are copolymerized by using 0.5% azobisisobutyronitrile asthe initia-' tor and toluene as the solvent medium. The reaction is carried out in crew cup vials at 75-80C. for 16 hours. The copolymer is then purified by adding methanol to the solution, filtered, redissolved in 1,2,2-trichlorotrifluoroethane, and this procedure is repeated three times. The solid polymer is then dried in a vacuum oven at 60C. for 64 hours. The intrinsic viscosity measured 'in hexafluorodimethyl benzene is 0.2.

A glass tube is then treated with a 5% 'trichloro trifluoroethylene solution of the copolymer by filling the tube, inverting it and allowing the excess liquid to drain out. Following evaporation of the solvent, the coated test tube is sterilized.

Five (5) ml of freshly drawn whole blood from the lower vena cava of a rabbit as added and the test tube is periodically tipped to observe clot formation. No evidence of clot formation is observed for severalhours. A control test tube, not coated with a layer of the co polymer, is tested in an identical manner, and clotting occurs within 7 minutes.

EXAMPLE 2 EXAMPLE 3 A copolymer of octadecyl vinyl ether with 1- dodecenoic'acid sodium salt is used to coat, from a 5% toluene solution, a commercially available 'fluoropolymer heart valve previously submitted to electron radiation to obtain better adhesion. It is then fluorinated in the dark by exposure to 5% fluorine diluted with nitrogen at room temperature for 2.weeks. The coated heart valve is then sterilized and when implanted in an animal, such as a dog, the implant, in accordance with EXAMPLE 4 A silicone rubber having a fluoroalkyl side chain is .prepared by the following customary procedure.

Methyl trichlorosilane is reacted with -l,1,2,2,3,3,4,4- octahydropentadecafluorohexadecyl magnesium chloride, the dichloro product separated from the reactive mixture by vacuum distillation and followed by polymerization with the addition of water. It is then mixed with 2% dimethyltindilaurate catalyst, molded into a tube of 0.05 inch inside diameter and cured at 150C. for 48 hours under nitrogen.

The tubing is tested in vivo using a jugular vein of a dog. The vein is exposed and severed in a standard surgical manner. The tube, after sterilization, is formed into a loop and to each end of the vein is attached one end of the tubing. Circulation through the vein is resumed and blood now is passing through the tubing.

The implanted artifical vein, in accordance with this invention, will not be found to be harmful to the life of the animal.

, EXAMPLE 5 l-perfluorooctadecene,'88.l g (0.1 mol), is copolymerized with maleic anhydride, 9.6 g(0.l mole), using a technique similar to that described in Example 1. The copolymer is then boiled in an aqueous sodium hydroxide solution containing a small amount of a fluorinated anionic surfactant. This reaction yields the sodium salt of the maleic acid portion of the polymer. The polymer is then purified by a repeated solutionpreceipitation technique.

A cannula made of polypropylene is surface oxidized in a circulating air oven at 1 10 C. to obtain better adhesion. It is then coated with a 5% trichlorotrifluoroethylene solution of the polymer prepared in this example and the'solvent evaporated in an air iven at 60C. After sterilization, the cannula is used as conduit replacement in a heart-lung machine. After several months of use no evidence of thrombus formation on the cannula will be reported.

EXAMPLE 6 Poly(vinyl alcohol) of 120,000 molecular weight, g(1 mole), is sulfated with-sulfur trioxide dissolved in sulfuric acid to yield the sulfate ester. As deduced by titration with sodium hydroxide one out of every 10 hydroxyl groups is sulfated. The polymer is further reacted with perfluorohexadecanoyl chloride in N- EXAMPLE 7 A 121' copolymer of methylvinylether maleic anhyclride, 15.6 g (0.1 mole) having an intrinsic viscosity of 2.5 in methylethyl ketone, is reacted in 500 ml of methylethyl ketone at the boil with l,l,2,2-tetrahydrohencosafluorododecyl amine, 66.3 g (0.1 mole). The fluorinated acid-amid is then precipitated in methanol, filtered, washed, and reacted with sodium hydroxide dissolved in alcohol. The polymer thus obtained. is polyco[methylvinyl ether-sodium salt of maleic acid mono( l l ,2,2-tetrahydrohencosafluorododecyl )amide], which is then purified by repeated solvationprecipitation.

The fluorinated copolymer is then molded in a hot press into a 0.05 in. inside diameter catheter having a wall thickness of 0.005 in. and sterilized. When surgically implanted in the jugular vein of a dog, similar results to those obtained in Example 4 will be reported.

EXAMPLE 8 Vinyl perfluorodocosyl ether, 11.8 g (0.1 mole) is polymerized and purified using a technique similar to that described in Example 1. The intrinsic viscosity measured in trichlorotrifluoroethane is 0.2. A stainless steel tubing is coated with a 5% trichlorotrifluoroethylene solution of this polymer, and the solvent evaporated at 60C. in a vacuum oven. After sterilization the tubing is used as an arterialvenous bypass in a hemidialysis machine. No thrombus formation will be evident after usage of the machine for several months.

EXAMPLE 9 A cannula made of polyethylene is phosphorilated on the surface with phosphorous trichloride at 60C. in the presence of oxygen, and then boiled in aqueous sodium hydroxide. This procedure provides sodium phosphate groups at the surface. A subsequent grafting of perfluorotetradecene using an electron radiation techniques yields the desired surface, which is then cleaned with bis(trifluoromethyl) benzene and ethanol. After through sterilization, the cannula, when tested in a heart-lung machine, will yield comparable result to those obtained in Example 5.

. EXAMPLE 10 101.6 grams (0.1 mole) of perfluorooctadecylperfluorovinyl ether and 16 grams (0.02 moles) of perfluoro-l-hexadecenoic acid are dissolved in bis(trifluoro)benzene and coated on a commercially available silicone rubber heart valve previously primed to obtain better adhesion. After'solvent evaporation, the coated heart valve is then irradiated with an electron beam of 5 MeV under argon to polymerize the coating. Following extraction of the residual monomers and sterilization, the heart valve, when evaluated as in Example 3, yields similar results.

It will be apparent that many widely different embodiments of this invention may be made without de parting from the spirit and scope thereof. Therefore, the invention is not intended to be limited except as indicated in the appended claims.

EXAMPLE. 11

Polyco(methacrylic acid-3,333,3,3'-hexafluoroisobutyl methacrylate) is prepared in emulsion at 65C for 6 hours with the following recipe, added in the order shown:

Parts Water 30.0 Trimethyloctodecylammonium bromide 1.0 Mcthacrylic'acid 2.0

- Contmued 3,3,3,3,3,3' hexafluoroisobutyl methacrylate 100 Acetone 1 5.0 Azodiisobutyramidine dihydrochloride 0.2

EXAMPLE 12 A thromboresistant artificial heart is molded from poly(methyl-3,3,3-trifluoropropyl siloxane) wherein about one fifth of the methyl groups is replaced with carboxyethyl groups. This copolymer is prepared as follows; Methyldichlorosilane is reacted with acrylonitrile under reflux conditions (60l,15C) for about ten hours by using catalytic amounts of the following materials: cuprous chloride, tetramethylethylene diamine and triethylamine. The reaction product, which is cyanoethyl-methyldichlorosilane, is hydrolyzed in the presenggg fam' HCl solution under reflux conditions until complete diappearance of the-nitrile group. After separation from theaqueous layer, the organic layer consists of poly(carboxyethylmethylsiloxane). This is equilibrated at 60100C, for 4-6 hours, with 20% by weight of 3,3,3-trifluoropropyl-methylsiloxane fluid commercially available from Dow Corning Co., Inc until constant viscosity is reached. The product is then washed with aqueous sodium carbonate, water, separate from the aqueous layer, and stripped off from the low boilers by distillation. It is then blended with 100 phr finely divided silica and 1 phr dicumyl peroxide, molded into a human heart and cured at 125C for 5 EXAMPLE l3 Acrylic acid, mole is copolymerized with. 80 mole of bis [2-(N-ethyl perfluorohexylsulfonamido) ethyl] itaconate, as in Example 1. After purification and coating on a test tube, the polymer passes the same test as the one described in Example '1.

Having thus described my invention and in what manner it may be manufactured and used, what I claim and desire to protect by Letters Patent is:

1.. A method-or maintaining the normal integrity of blood which comprises placing it in contact with a physiologically acceptable article at least the surface of which consists of an organic polymeric material having fluoroalkyl side chains of the formula C F C H wherein n and m are integers, n ranging 1 to 28, and the sum of n and m from 2 to 28, the number of said fluoroalkyl side chains relative to the number of main chain atoms in one recurring unit ranges from 1:2 to 1:10; and said polymeric material having another side group chemically bonded to the main chain, said side group being selected from the group consisting of Hydrogen, hologen, aryl, lower alkyl and anionic groups.

2. The method defined in'claim 1 wherein the said fiuoroalkyl side chains are linear, the said integers n and m range from 8 to 28 and the sum of n and m from 8 to 28.

3. The method definedin claim 1 wherein the said integer n ranges from 1 to 7, the sum of n and m from 2 to 28 and the said side group is an anionic group.

4. The method defined in claim 1 wherein said physi- 5 ological acceptable article comprises a substrate portion and a surface coating. portion, said surface coating portion at least being of said polymeric material defined in claiml.

5. The method defined in claim 1 wherein the said anionic group is a member selected from the group the said organic polymeric material by an intermediate divalent radical.

8. The method defined in claim 1 wherein the said anionic group is bonded to the said organic polymeric material by an intermediate divalent radical.

9. The method defined in claim 7 wherein the said intermediate divalent radical is a member selected from the group consisting of O, -'CO,v SO,

10. The method defined in claim 8 wherein the said intermediate divalent radical is a member selected from the group consisting of --CH C H *OCZHQ, 2)B' F2)15 'f z H z 11. The method defined in claim 1 wherein said physiologically acceptable article is a subdermal surgical implant.

12. The method defined in claim 1 wherein said physiologically acceptable article is a surgical instrument.

13. The method defined in claim 1 wherein said physiologically acceptable article is a laboratory apparatus used for handling blood.

14. The method defined in claim 1 wherein said physiologically acceptable article is a blood container.

15. The method defined in claim 4 wherein the said substrate portion is selected from the group consisting of plastics, rubbers, metals, glass and ceramics.

16. The method defined in claim l wherein said organic polymeric material is selected from the group consisting of copolymers prepared from a fiuoroalkyl acrylate and acrylic acid, a fiuoroalkyl methacrylate and methacrylic acid and the mixtures of these monomers.

17. The method defined in claim 16 wherein said polymeric acrylates are selected from the group consisting of:

poly(l,ldihydropentacosafluorotridecyl acrylate) poly( 1 l -dihydropentatetracontafluorotricosyl methacrylate) polyco( l l dihydropentadecafluorooctyl methacrylate 10% sodium acrylate) polyco(1,1,2,2-tetrahydrotrifluoropropyl acrylate 5% maleic acid) polyco( 1 l ,2,2tetrahydropentadecafluorononyl acrylate 30% methacrylic acid 15% sodium methacrylate) 12 19. The method defined in claim 1 wherein said organic polymeric material is selected from the group consisting of:

polymers of fluoroalkyl esters, amides and imides of maleic and fumaric acids, the copolymers with ethylene, styrene, methylvinyl ether and vinyl acetate of fluoroalkyl esters, amides and imides of maleic and fumaric acids, the copolymers with maleic, fumaric and acrylic acids and their anhydrides of fluoroalkyl esters,

amides and imides of maleic and fumaric acids.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3633578 *Jun 24, 1970Jan 11, 1972American Cyanamid CoMethod of maintaining the integrity of blood
US3663288 *Sep 4, 1969May 16, 1972American Cyanamid CoPhysiologically acceptible elastomeric article
US3722599 *Aug 17, 1971Mar 27, 1973Minnesota Mining & MfgFluorocyanoacrylates
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US4008047 *Dec 26, 1974Feb 15, 1977North Star Research InstituteBlood compatible polymers for blood oxygenation devices
US4178329 *May 5, 1978Dec 11, 1979Hoechst AktiengesellschaftPlastics material having an improved blood tolerance
US4219520 *Aug 30, 1978Aug 26, 1980Medical Evaluation Devices And Instruments Corp.Coating with cationic surfactant to make heparin-receptive
US4484894 *Feb 23, 1982Nov 27, 1984Eiichi MasuharaSheet for lining denture base
US4622237 *Jun 11, 1985Nov 11, 1986Giulio LoriPlastics, laminates, metals
US4632842 *Jun 20, 1985Dec 30, 1986Atrium Medical CorporationGlow discharge process for producing implantable devices
US4656083 *Mar 11, 1985Apr 7, 1987Washington Research FoundationVascular prosthetics
US4687482 *Apr 27, 1984Aug 18, 1987Scripps Clinic And Research FoundationVascular prosthesis
US4718907 *Jun 20, 1985Jan 12, 1988Atrium Medical CorporationPolytetrafluoroethylene coated polyethylene terephthalate
US4994298 *Apr 18, 1990Feb 19, 1991Biogold Inc.Method of making a biocompatible prosthesis
US5034265 *Aug 21, 1989Jul 23, 1991Washington Research FoundationPlasma gas discharge treatment for improving the compatibility of biomaterials
US5356668 *Dec 9, 1991Oct 18, 1994Vascutek LimitedFluorinating polymer surfaces
US5383903 *Aug 20, 1992Jan 24, 1995United States Surgical CorporationDimethylsiloxane-alkylene oxide copolymer coatings for filaments
US5637113 *Dec 13, 1994Jun 10, 1997Advanced Cardiovascular Systems, Inc.Polymer film for wrapping a stent structure
US5700286 *Aug 22, 1996Dec 23, 1997Advanced Cardiovascular Systems, Inc.Polymer film for wrapping a stent structure
US5907017 *Jan 31, 1997May 25, 1999Cornell Research Foundation, Inc.Semifluorinated side chain-containing polymers
US6022344 *Dec 4, 1997Feb 8, 2000Npbi International B.V.Cryopreservation bag
US6060639 *Mar 4, 1994May 9, 2000Mentor CorporationTesticular prosthesis and method of manufacturing and filling
US6114467 *Aug 11, 1998Sep 5, 2000Cornell Research Foundation, Inc.Antisticking, nonwetting, stability
US6464723Apr 22, 1999Oct 15, 2002Advanced Cardiovascular Systems, Inc.Radiopaque stents
US6527801Apr 13, 2000Mar 4, 2003Advanced Cardiovascular Systems, Inc.Biodegradable drug delivery material for stent
US6585757Sep 15, 1999Jul 1, 2003Advanced Cardiovascular Systems, Inc.Endovascular stent with radiopaque spine
US6602287Dec 8, 1999Aug 5, 2003Advanced Cardiovascular Systems, Inc.Preventing coagulation on surfaces of graft medical equipment by applying coatings such as octafluoropropane and overcoatings comprising artery and/or vein cell lining mimetics
US6605114Oct 29, 1999Aug 12, 2003Advanced Cardiovascular Systems, Inc.Heparin delivery method
US6652579Jun 22, 2000Nov 25, 2003Advanced Cardiovascular Systems, Inc.Radiopaque stent
US6776792Apr 24, 1997Aug 17, 2004Advanced Cardiovascular Systems Inc.Coated endovascular stent
US7077860Jun 24, 2004Jul 18, 2006Advanced Cardiovascular Systems, Inc.Method of reducing or eliminating thrombus formation
US7105018Dec 30, 2002Sep 12, 2006Advanced Cardiovascular Systems, Inc.Drug-eluting stent cover and method of use
US7144422Nov 13, 2002Dec 5, 2006Advanced Cardiovascular Systems, Inc.Drug-eluting stent and methods of making the same
US7163715Dec 30, 2002Jan 16, 2007Advanced Cardiovascular Systems, Inc.Spray processing of porous medical devices
US7186789Jun 11, 2003Mar 6, 2007Advanced Cardiovascular Systems, Inc.nonfouling surfaces; block copolyesters having a biobeneficial moiety that provides a biological benefit without releasing pharmaceutically active agent; condensation polymerization
US7198675Sep 30, 2003Apr 3, 2007Advanced Cardiovascular SystemsStent mandrel fixture and method for selectively coating surfaces of a stent
US7201940Jun 12, 2001Apr 10, 2007Advanced Cardiovascular Systems, Inc.Applying the coating material to the medical device by cold spray thermal processing wherein powder particles are introduced into a high pressure gas where both the gas and particles enter a supersonic jet which is directed against the medical device forming a porous coating
US7229471Sep 10, 2004Jun 12, 2007Advanced Cardiovascular Systems, Inc.Compositions containing fast-leaching plasticizers for improved performance of medical devices
US7258891Apr 7, 2003Aug 21, 2007Advanced Cardiovascular Systems, Inc.Reduct coating, controlling thickness in support contactor zones
US7285304Jun 25, 2003Oct 23, 2007Advanced Cardiovascular Systems, Inc.Coating the device with a polymer, an active agent and a solvent; evaporating the solvent; and applying a polymer-free fluid to the dry coating to increase the crystallinity of the polymer
US7291166May 18, 2005Nov 6, 2007Advanced Cardiovascular Systems, Inc.Polymeric stent patterns
US7297159Jul 21, 2004Nov 20, 2007Advanced Cardiovascular Systems, Inc.Selective coating of medical devices
US7297758Aug 2, 2005Nov 20, 2007Advanced Cardiovascular Systems, Inc.Method for extending shelf-life of constructs of semi-crystallizable polymers
US7301001Dec 20, 2006Nov 27, 2007Advanced Cardiovascular Systems, Inc.Bioabsorbable, biobeneficial polyester polymers for stent coatings
US7312299Dec 20, 2006Dec 25, 2007Advanced Cardiovascular Systems, Inc.Nonfouling surfaces; block copolyesters having a biobeneficial moiety that provides a biological benefit without releasing pharmaceutically active agent; condensation polymerization; for medical implants
US7329366Jun 18, 2004Feb 12, 2008Advanced Cardiovascular Systems Inc.Method of polishing implantable medical devices to lower thrombogenecity and increase mechanical stability
US7381048Apr 12, 2005Jun 3, 2008Advanced Cardiovascular Systems, Inc.Stents with profiles for gripping a balloon catheter and molds for fabricating stents
US7390333Jan 10, 2003Jun 24, 2008Advanced Cardiovascular Systems, Inc.Biodegradable drug delivery material for stent
US7413574Aug 1, 2006Aug 19, 2008Advanced Cardiovascular Systems, Inc.Drug-eluting stent cover method of use
US7416558Aug 1, 2006Aug 26, 2008Advanced Cardiovascular Systems, Inc.Drug-eluting stent cover and method of use
US7435255Sep 22, 2003Oct 14, 2008Advnaced Cardiovascular Systems, Inc.Drug-eluting stent and methods of making
US7470283Jan 10, 2003Dec 30, 2008Advanced Cardiovascular Systems, Inc.Biodegradable drug delivery material for stent
US7476245Aug 16, 2005Jan 13, 2009Advanced Cardiovascular Systems, Inc.Polymeric stent patterns
US7514122Oct 17, 2006Apr 7, 2009Advanced Cardiovascular Systems, Inc.Coating a consolidated biocompatible medical device such as a stent by directing a supersonic jet of high pressure gas and particles to form a functionally graded coating to allow direct control of drug elution without an additional polymer topcoat; applying a drug to the coating
US7553377Apr 27, 2004Jun 30, 2009Advanced Cardiovascular Systems, Inc.Apparatus and method for electrostatic coating of an abluminal stent surface
US7563324Dec 29, 2003Jul 21, 2009Advanced Cardiovascular Systems Inc.System and method for coating an implantable medical device
US7604700Jan 16, 2007Oct 20, 2009Advanced Cardiovascular Systems, Inc.Stent mandrel fixture and method for selectively coating surfaces of a stent
US7622070Jun 20, 2005Nov 24, 2009Advanced Cardiovascular Systems, Inc.Tubing-mandrels; stents
US7632307Dec 16, 2004Dec 15, 2009Advanced Cardiovascular Systems, Inc.Abluminal, multilayer coating constructs for drug-delivery stents
US7658880Jul 29, 2005Feb 9, 2010Advanced Cardiovascular Systems, Inc.Polymeric stent polishing method and apparatus
US7662326Apr 27, 2007Feb 16, 2010Advanced Cardiovascular Systems, Inc.Compositions containing fast-leaching plasticizers for improved performance of medical devices
US7699890Jan 28, 2004Apr 20, 2010Advanced Cardiovascular Systems, Inc.Medicated porous metal prosthesis and a method of making the same
US7708548Apr 10, 2008May 4, 2010Advanced Cardiovascular Systems, Inc.Molds for fabricating stents with profiles for gripping a balloon catheter
US7731890Jun 15, 2006Jun 8, 2010Advanced Cardiovascular Systems, Inc.conveying a gas into a poly(L-lactide) tube disposed within a cylindrical mold to increase pressure inside tube, wherein increased pressure radially expands tube to conform to inside surface of the mold, applying tension along axis of the tube to axially extend tube, fabricating stent from expanded tube
US7740791Jun 30, 2006Jun 22, 2010Advanced Cardiovascular Systems, Inc.Method of fabricating a stent with features by blow molding
US7757543Jul 13, 2006Jul 20, 2010Advanced Cardiovascular Systems, Inc.Radio frequency identification monitoring of stents
US7758881Mar 24, 2005Jul 20, 2010Advanced Cardiovascular Systems, Inc.stents having everolimus and clobetasol; restenosis, vulnerable plaque; biodegradable
US7761968May 25, 2006Jul 27, 2010Advanced Cardiovascular Systems, Inc.Method of crimping a polymeric stent
US7794495Jul 17, 2006Sep 14, 2010Advanced Cardiovascular Systems, Inc.A stent having a structural element made of a polymer with a hydrolytically degradable L-lactide block and a polystyrenesulfonate or poly(2-acrylamido-2-methylpropanesulfonic acid) block in which the acid group is protecting group; when deprotected the acid group initiates degradation
US7794776Jun 29, 2006Sep 14, 2010Abbott Cardiovascular Systems Inc.modifying molecular weight, comprises polyester amide coating; improving degradation rate and drug release rate
US7823263Jul 9, 2007Nov 2, 2010Abbott Cardiovascular Systems Inc.Method of removing stent islands from a stent
US7829008May 30, 2007Nov 9, 2010Abbott Cardiovascular Systems Inc.Fabricating a stent from a blow molded tube
US7842737Sep 29, 2006Nov 30, 2010Abbott Cardiovascular Systems Inc.Polymer blend-bioceramic composite implantable medical devices
US7867547Dec 19, 2005Jan 11, 2011Advanced Cardiovascular Systems, Inc.spray coating with anti-coagulant, platelet inhibitor and/or pro-healing substance; cured via electrical resistance heater
US7875233Jul 18, 2005Jan 25, 2011Advanced Cardiovascular Systems, Inc.Method of fabricating a biaxially oriented implantable medical device
US7875283Jun 16, 2005Jan 25, 2011Advanced Cardiovascular Systems, Inc.A stent coated with hydrophobic polymer having water-labile bonds and strength to withstand forces of the vascular systems and also biodegrades on its surface rather than bulk erosion; mechanical properties; drug delivery; a polyester,-anhydride or -amide having the monomer, trimellitylimidotyrosine
US7886419Jul 18, 2006Feb 15, 2011Advanced Cardiovascular Systems, Inc.Stent crimping apparatus and method
US7901452Jun 27, 2007Mar 8, 2011Abbott Cardiovascular Systems Inc.Method to fabricate a stent having selected morphology to reduce restenosis
US7923022Sep 13, 2006Apr 12, 2011Advanced Cardiovascular Systems, Inc.stent body is made of polylactone copolymer consisting of monomers selected from lactic acid, glycolic acid and hydroxyhexanoic acid; copolymerized in solvent; mechanical stability, nonbrittleness, fracturing resist
US7951185Jan 6, 2006May 31, 2011Advanced Cardiovascular Systems, Inc.Delivery of a stent at an elevated temperature
US7951194May 22, 2007May 31, 2011Abbott Cardiovascular Sysetms Inc.Bioabsorbable stent with radiopaque coating
US7955381Jun 29, 2007Jun 7, 2011Advanced Cardiovascular Systems, Inc.Polymer-bioceramic composite implantable medical device with different types of bioceramic particles
US7959857Jun 1, 2007Jun 14, 2011Abbott Cardiovascular Systems Inc.Radiation sterilization of medical devices
US7959940May 30, 2006Jun 14, 2011Advanced Cardiovascular Systems, Inc.Polymer-bioceramic composite implantable medical devices
US7964210Mar 31, 2006Jun 21, 2011Abbott Cardiovascular Systems Inc.Degradable polymeric implantable medical devices with a continuous phase and discrete phase
US7967998Jan 3, 2008Jun 28, 2011Advanced Cardiocasvular Systems, Inc.Method of polishing implantable medical devices to lower thrombogenecity and increase mechanical stability
US7971333May 30, 2006Jul 5, 2011Advanced Cardiovascular Systems, Inc.Manufacturing process for polymetric stents
US7989018Mar 31, 2006Aug 2, 2011Advanced Cardiovascular Systems, Inc.Fluid treatment of a polymeric coating on an implantable medical device
US7998404Jul 13, 2006Aug 16, 2011Advanced Cardiovascular Systems, Inc.Reduced temperature sterilization of stents
US8003156May 4, 2006Aug 23, 2011Advanced Cardiovascular Systems, Inc.Rotatable support elements for stents
US8007529Aug 1, 2008Aug 30, 2011Advanced Cardiovascular Systems, Inc.Medicated porous metal prosthesis
US8016879Jun 27, 2007Sep 13, 2011Abbott Cardiovascular Systems Inc.Drug delivery after biodegradation of the stent scaffolding
US8017237Jun 23, 2006Sep 13, 2011Abbott Cardiovascular Systems, Inc.Nanoshells on polymers
US8034287May 15, 2007Oct 11, 2011Abbott Cardiovascular Systems Inc.Radiation sterilization of medical devices
US8043553Sep 30, 2004Oct 25, 2011Advanced Cardiovascular Systems, Inc.Controlled deformation of a polymer tube with a restraining surface in fabricating a medical article
US8048441Jun 25, 2007Nov 1, 2011Abbott Cardiovascular Systems, Inc.Nanobead releasing medical devices
US8048448Jun 15, 2006Nov 1, 2011Abbott Cardiovascular Systems Inc.Nanoshells for drug delivery
US8099849Dec 13, 2006Jan 24, 2012Abbott Cardiovascular Systems Inc.Optimizing fracture toughness of polymeric stent
US8109994Jan 2, 2008Feb 7, 2012Abbott Cardiovascular Systems, Inc.Biodegradable drug delivery material for stent
US8128687Aug 25, 2006Mar 6, 2012Advanced Cardiovascular Systems, Inc.Drug-eluting stent with filament strands
US8128688Jun 19, 2007Mar 6, 2012Abbott Cardiovascular Systems Inc.Carbon coating on an implantable device
US8172897Jun 28, 2004May 8, 2012Advanced Cardiovascular Systems, Inc.Polymer and metal composite implantable medical devices
US8173062Sep 30, 2004May 8, 2012Advanced Cardiovascular Systems, Inc.Controlled deformation of a polymer tube in fabricating a medical article
US8197879Jan 16, 2007Jun 12, 2012Advanced Cardiovascular Systems, Inc.Method for selectively coating surfaces of a stent
US8202528Jun 5, 2007Jun 19, 2012Abbott Cardiovascular Systems Inc.Implantable medical devices with elastomeric block copolymer coatings
US8241554Jun 29, 2004Aug 14, 2012Advanced Cardiovascular Systems, Inc.Method of forming a stent pattern on a tube
US8262723Apr 9, 2007Sep 11, 2012Abbott Cardiovascular Systems Inc.Implantable medical devices fabricated from polymer blends with star-block copolymers
US8293260Jun 5, 2007Oct 23, 2012Abbott Cardiovascular Systems Inc.Elastomeric copolymer coatings containing poly (tetramethyl carbonate) for implantable medical devices
US8293367Jul 15, 2011Oct 23, 2012Advanced Cardiovascular Systems, Inc.Nanoshells on polymers
US8333000Jun 19, 2006Dec 18, 2012Advanced Cardiovascular Systems, Inc.Methods for improving stent retention on a balloon catheter
US8343530Dec 22, 2006Jan 1, 2013Abbott Cardiovascular Systems Inc.Polymer-and polymer blend-bioceramic composite implantable medical devices
US8414642Dec 1, 2008Apr 9, 2013Advanced Cardiovascular Systems, Inc.Biodegradable stent of a polyorthoester polymer or a polyanhydride polymer
US8425591Jun 11, 2007Apr 23, 2013Abbott Cardiovascular Systems Inc.Methods of forming polymer-bioceramic composite medical devices with bioceramic particles
US8435550Aug 13, 2008May 7, 2013Abbot Cardiovascular Systems Inc.Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US8465789Jul 18, 2011Jun 18, 2013Advanced Cardiovascular Systems, Inc.Rotatable support elements for stents
US8470014Aug 14, 2007Jun 25, 2013Advanced Cardiovascular Systems, Inc.Stent-catheter assembly with a releasable connection for stent retention
US8486135Apr 9, 2007Jul 16, 2013Abbott Cardiovascular Systems Inc.Implantable medical devices fabricated from branched polymers
US8535372Jun 18, 2007Sep 17, 2013Abbott Cardiovascular Systems Inc.Bioabsorbable stent with prohealing layer
US8568469Jun 28, 2004Oct 29, 2013Advanced Cardiovascular Systems, Inc.Stent locking element and a method of securing a stent on a delivery system
US8585754Jan 13, 2012Nov 19, 2013Abbott Cardiovascular Systems Inc.Stent formed of a Biodegradable material
US8592036Sep 20, 2012Nov 26, 2013Abbott Cardiovascular Systems Inc.Nanoshells on polymers
US8596215Jul 18, 2011Dec 3, 2013Advanced Cardiovascular Systems, Inc.Rotatable support elements for stents
US8603530Jun 14, 2006Dec 10, 2013Abbott Cardiovascular Systems Inc.Nanoshell therapy
US8637110Jul 18, 2011Jan 28, 2014Advanced Cardiovascular Systems, Inc.Rotatable support elements for stents
US8741379Jul 18, 2011Jun 3, 2014Advanced Cardiovascular Systems, Inc.Rotatable support elements for stents
DE2945138A1 *Nov 8, 1979May 29, 1980Peter John FydelorBiokompatibles material und seine verwendung
DE3709069A1 *Mar 19, 1987Oct 1, 1987Ohi Seisakusho Co LtdDrahtbefestigungseinrichtung fuer eine fenster-reguliervorrichtung
EP0061312A1 *Mar 18, 1982Sep 29, 1982Board Of Regents The University Of Texas SystemAlkyl-substituted polymers having enhanced albumin affinity
EP0073978A2 *Aug 18, 1982Mar 16, 1983Asahi Glass Company Ltd.Antithrombogenic materials
EP0076714A1 *Sep 13, 1982Apr 13, 1983COMMISSARIAT A L'ENERGIE ATOMIQUE Etablissement de Caractère Scientifique Technique et IndustrielPolymeric bone joint prosthesis and method of preparing the same
EP0873756A2 *Mar 13, 1998Oct 28, 1998Hüls AktiengesellschaftAntibacterial blood compatible modified surfaces
WO1988006026A2 *Feb 17, 1988Aug 25, 1988Alberto ArpesaniInternal prosthesis for the substitution of a part of the human body particularly in vascular surgery
Classifications
U.S. Classification424/422, 428/421, 433/169, 623/1.1
International ClassificationA61K6/08, A61F2/06, A61L33/06, A61F2/00, A61K6/083
Cooperative ClassificationA61F2/0077, A61F2/06, A61K6/08, A61K6/083, A61L33/066
European ClassificationA61K6/083, A61L33/06B2, A61K6/08, A61F2/06, A61F2/00L